Drug Trial Radar · NCT05832931
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1
Last checked: Nov 19, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
362
Actual
Start
Apr 28, 2023
Primary completion
Jul 28, 2025
Study completion Jul 28, 2025
Sponsor
- Lead sponsor
- Pathalys PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Launch Therapeutics
- First posted
- Apr 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases. First, a placebo-controlled, double-blind phase where patients will be randomly assigned to either receive dose-titrated PLS240 or matching placebo for 27 weeks. After the completion of the double-blind phase, patients will be eligible to enroll in the open-label extension phase, where they will receive dose-titrated PLS240 for an additional 26 weeks. Throughout the duration of the study, patients will be expected to attend multiple study visits where an investigator will collect blood, preform electrocardiograms (ECGs) and physical exams, and further assess the safety and efficacy of PLS240.
Conditions
- Secondary Hyperparathyroidism
- End-stage Kidney Disease (ESKD)
Interventions
PLS240Drug
Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.
PlaceboDrug
Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.
Open-Label Extension PLS240Drug
Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double-Blind Phase: Proportion of PLS240 treated participants compared to placebo treated participants with a ≥30% decrease in mean iPTHTime frame: each visit from screening through week 27
- Open-Label Phase: Proportion of participants with a corrected serum calcium (cCa) <7.5 mg/dLTime frame: up to week 28
- Open-Label Phase: Proportion of participants with a corrected serum calcium (cCa) <8.3 mg/dLTime frame: up to week 28
- Open-Label Phase: Number of Adverse Events (AEs)Time frame: up to week 28
- Open-Label Phase: Number of Serious Adverse Events (SAEs)Time frame: up to week 28
Locations
68 sites in 6 countries. Site status is shown where the registry gives one.
Site Number: USA016-1
Pine Bluff, Arkansas
Site Number: USA032-1
Anaheim, California
Site Number: USA031-1
Beverly Hills, California
Site Number: USA020-1
Fairfield, California
Site Number: USA023-1
Fullerton, California
Site Number: USA030-1
Glendale, California
Site Number: USA045-1
Oxnard, California
Site Number: USA046-1
Riverside, California
Site Number: USA035-1
Salinas, California
Site Number: USA001-1
San Diego, California
Site Number: USA021-1
San Diego, California
Site Number: USA019-1
San Dimas, California
Site Number: USA036-1
Whittier, California
Site Number: USA018-1
Denver, Colorado
Site Number: USA003-1
Lone Tree, Colorado
Site Number: USA009-1
Hartford, Connecticut
Site Number: USA042-1
Coral Gables, Florida
Site Number: USA055-1
Coral Gables, Florida
Site Number: USA034-1
Hollywood, Florida
Site Number: USA053-1
Atlanta, Georgia
Site Number: USA013-1
Dalton, Georgia
Site Number: USA027-1
Boise, Idaho
Site Number: USA007-1
Shelbyville, Indiana
Site Number: USA026-1
Baton Rouge, Louisiana
Site Number: USA015-1
Columbus, Mississippi
Site Number: USA028-1
Oxford, Mississippi
Site Number: USA022-1
Kansas City, Missouri
Site Number: USA017-1
Las Vegas, Nevada
Site Number: USA010-1
Jersey City, New Jersey
Site Number: USA008-1
Gallup, New Mexico
Site Number: USA039-1
Manhasset, New York
Site Number: USA011-1
The Bronx, New York
Site Number: USA052-1
Charlotte, North Carolina
Site Number: USA043-1
Greenville, North Carolina
Site Number: USA033-1
Winston-Salem, North Carolina
Site Number: USA040-1
Spartanburg, South Carolina
Site Number: USA049-1
Knoxville, Tennessee
Site Number: USA037-1
Arlington, Texas
Site Number: USA024-1
Austin, Texas
Site Number: USA056-1
Fort Worth, Texas
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.